Japanese, U.K. Funds Propose Taking Kobayashi Pharma Private
Tokyo, Sept. 25 (Jiji Press)--Kobayashi Pharmaceutical Co. is considering going private, with a consortium of Japanese and British investment funds having proposed acquiring the company and overhauling its management, sources said Friday. According to the sources, Japan's Nippon Sangyo Suishin Kiko Ltd. and Britain's CVC Capital Partners PLC have proposed a tender offer for the Japanese drugm...
Tokyo, September 25 (Jiji Press)--A consortium of Japanese and British investment funds is reportedly considering acquiring Kobayashi Pharmaceutical Co. and restructuring its management, sources disclosed on Friday. The investors include Japan’s Nippon Sangyo Suishin Kiko Ltd. and Britain’s CVC Capital Partners PLC, who have jointly proposed a tender offer for the pharmaceutical company in collaboration with its founding family, a significant stakeholder.
Kobayashi Pharmaceutical confirmed in a statement on Friday that it "received a preliminary, non-binding joint proposal from entities associated with NSSK and CVC Capital Partners concerning a potential take-private transaction as a potential means to augment the company's corporate value," although the company emphasized that no decisions have been made regarding the matter at present.
The Tokyo Stock Exchange's Prime section-listed firm could be valued at approximately 500 billion yen in a potential takeover. Kobayashi Pharmaceutical has been implementing management reforms, such as enhancing its quality-control procedures, following the revelation of health issues associated with its supplements containing "beni koji" red yeast rice in 2024.
Written by urgent.news from Nippon.com News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
